Benzinga | Apr 15, 2021 07:06AM EDT

Castle Biosciences Highlights Presentation Of New Independent Validation Study Of i31-GEP Artificial Intelligence Algorithm

i31-GEP integrates DecisionDx-Melanoma continuous score with clinicopathologic factors designed to provide a more precise, personalized likelihood of sentinel lymph node positivity

Castle Biosciences, Inc. (NASDAQ:CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, presented new data on the integration of the DecisionDx(r)-Melanoma test with clinicopathologic features (i31-GEP) at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology (EADO) Congress. DecisionDx-Melanoma is Castle's prognostic gene expression profile test for cutaneous melanoma with an Integrated Test Result (ITR) designed to provide a more precise risk prediction in patients with stage I, II or III melanoma.

The ITR is calculated by the independently validated integrated 31-GEP, or i31-GEP, algorithm, designed to provide a more precise and personalized prediction of sentinel lymph node (SLN) positivity in order to guide discussions and recommendations, within current risk-based guidelines, for the SLN biopsy (SLNB) surgical procedure. i31-GEP is an artificial intelligence-based neural network algorithm that integrates the DecisionDx-Melanoma test result with the patient's traditional clinicopathologic features. The algorithm has been validated in a cohort of 1,674 prospectively tested patients with T1-T4 cutaneous melanoma.

The poster, titled "Integration of the 31-gene expression profile test with clinicopathologic features (i31-GEP) to assess sentinel lymph node positivity risk in patients with cutaneous melanoma," highlights the i31-GEP validation study data and demonstrates that the algorithm provides a more precise, personalized likelihood of sentinel lymph node positivity. The poster can be accessed here.